ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023
Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Evaluating eight smoking metrics for modelling survival in non-small cell lung cancer.Cancer epidemiology · 2026Pooled it
- Racial and ethnic disparities in receipt of guideline-concordant treatment for early-stage non-small cell lung cancer.Cancer causes & control : CCC · 2026Article
- Multifactorial Impact of Age, Race, and Female Sex on Management of Non-small Cell Lung Cancer.Annals of surgical oncology · 2026Article
- Blood eosinophil counts and postoperative outcomes in early-stage lung cancer: a retrospective cohort study.Respiratory research · 2026Article
- ERS Congress 2025: highlights from the Thoracic Oncology Assembly.ERJ open research · 2026Article
- Burden and Impact of Frailty and Comorbidity in Individuals Screened for Lung Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Association of automated quantified emphysema and interstitial lung abnormality with survival in non-small cell lung cancer.Insights into imaging · 2026Article
- Lung cancer across borders: From molecular epidemiology to precision treatment strategies.Therapeutic advances in medical oncology · 2026Article
- Economic and Humanistic Burden of Multimorbidity in the United States: A Longitudinal Study of Expenditure and Quality of Life Trajectories, 2019-2022.International journal of environmental research and public health · 2025Article
- The - 216G/T polymorphism in the EGFR gene: A review focusing on Non-Small lung cancer.Molecular biology reports · 2025Review
- A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.Cancers · 2025Review
- Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Article
- Genome-wide association study of early-stage non-small cell lung cancer prognosis: a pooled analysis in the International Lung Cancer Consortium.Carcinogenesis · 2025Article
- Respiratory Function as a Prognostic Factor for Lung Cancer in Screening and General Populations.Annals of the American Thoracic Society · 2025Article
- [Prognosis-guided optimization of intensity-modulated radiation therapy plans for lung cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Cardiotoxicity following thoracic radiotherapy for lung cancer.British journal of cancer · 2025Review
- A pan-cancer analysis of the prognostic and immunological roles of zinc finger protein 514 in human tumors.Frontiers in oncology · 2025Article
- Are comorbidities associated with differences in healthcare charges among lung cancer patients in US hospitals? Focusing on variances by patient and socioeconomic factors.Chronic illness · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
23 authors at 16 institutions in 10 countries.
Funding
Abstract
introductionWe explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer-specific survival (LCSS), by stage, in a large, multicontinent NSCLC pooled data set.
methodsOn the basis of patients pooled from 11 International Lung Cancer Consortium studies with available respiratory and cardiometabolic comorbidity data, adjusted hazard ratios (aHRs) were estimated using Cox models for OS. LCSS was evaluated using competing risk Grey and Fine models and cumulative incidence functions. Logistic regression (adjusted OR [aOR]) was applied to assess factors associated with surgical resection.
resultsOS analyses used patients with NSCLC with respiratory health or cardiometabolic health data (N = 16,354); a subset (n = 11,614) contributed to LCSS analyses. In stages I to IIIA NSCLC, patients with respiratory comorbidities had worse LCCS (stage IA aHR = 1.51, confidence interval [CI]: 1.17-1.95; stages IB-IIIA aHR = 1.20, CI: 1.06-1.036). In contrast, patients with stages I to IIIA NSCLC with cardiometabolic comorbidities had a higher risk of death from competing (non-NSCLC) causes (stage IA aHR = 1.34, CI: 1.12-1.69). The presence of respiratory comorbidities was inversely associated with having surgical resection (stage IA aOR = 0.54, CI: 0.35-0.83; stages IB-IIIA aOR = 0.57, CI: 0.46-0.70).
conclusionsThe presence of either cardiometabolic or respiratory comorbidities is associated with worse OS in stages I to III NSCLC. Patients with respiratory comorbidities were less likely to undergo surgery and had worse LCSS, whereas patients with cardiometabolic comorbidities had a higher risk of death from competing causes. As more treatment options for stages I to III NSCLC are introduced into the practice, accounting for cardiometabolic and respiratory comorbidities becomes essential in trial interpretation and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.